Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02947165
Title Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups:
Covered Countries USA | ITA | DEU | CHE | CAN | AUT

Facility Status City State Zip Country Details
Sarah Cannon Research Institute SC Nashville Tennessee 37203 United States Details
Huntsman Cancer Institute SC Salt Lake City Utah 84112 United States Details
Novartis Investigative Site Salzburg 5020 Austria Details
Novartis Investigative Site Toronto Ontario M5G 2C1 Canada Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Wuerzburg 97080 Germany Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Milano MI 20132 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Kashiwa Chiba 277 8577 Japan Details
Novartis Investigative Site St. Gallen 9007 Switzerland Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field